Sector Pharmaceuticals & Biotech. - Latest news, views and updates

Pharmaceuticals & Biotech.

SECTOR | 20 Feb 2025, 09:21PM

Pharma Sector Q3 Review: Lupin, Cipla Lead As Chronic Therapies Outshine Acute Drugs

NDTV Profit

Nuvama found that the slowdown in anti-infective therapy and respiratory drugs is persistent.

Pharmaceuticals & Biotech.

SECTOR | 19 Feb 2025

Top Conviction Ideas - Pharmaceutical & Hospitals

Pharmaceuticals & Biotech.

Axis Direct

Top Conviction Ideas (Pharma and Hospital) - Max Healthcare; Lupin; Fortis Healthcare.

Pharmaceuticals & Biotech.

SECTOR | 17 Feb 2025

South African NGOs worry Trump's aid freeze will disrupt HIV treatment

Business Standard

At a rural village in South Africa's KwaZulu-Natal province, unemployed 19-year-old Nozuko Majola is trying to figure out if she has enough money for the one-hour ride to collect her much-needed HIV medication, usually delivered to her home that can't be easily reached due to rough, untarred roads. Majola is one of millions of patients in South Africa affected by US President Donald Trump's global foreign aid freeze, raising worries about HIV patients defaulting on treatment, infection rates going up and eventually a rise in deaths. In 2024, think tank Human Sciences Research Council released figures showing that Majola's province recorded the second-highest HIV prevalence in the country, at 16 per cent, with at least 1,300 young people estimated to contract the disease every week. KwaZulu-Natal also had the highest number of people living with HIV in South Africa in 2022, about 19,80,000. The country counts more than 7.5 million people infected with the virus that causes AIDS -- mo

Pharmaceuticals & Biotech.

SECTOR | 16 Feb 2025

Aurobindo Pharma to commence supplies to Europe from China plant in April

Business Line

The Hyderabad-based drug maker commenced operations at the facility in the last week of November 2024 and is now ramping up the production

Aurobindo Pharma to begin supplies to Europe from China plant in April

Business Standard | 16 Feb 2025

Pharmaceuticals & Biotech.

SECTOR | 10 Feb 2025

HIV infections likely to surge 6-fold if US support ends: UNAIDS chief

Business Standard

The head of the UN AIDS agency said on Monday the number of new HIV infections could jump more than six times by 2029 if American support of the biggest AIDS programme is dropped, warning that millions of people could die and more resistant strains of the disease could emerge. In an interview with The Associated Press, UNAIDS Executive Director Winnie Byanyima said HIV infections have been falling in recent years, with just 1.3 million new cases recorded in 2023, a 60 per cent decline since the virus peaked in 1995. But since President Donald Trump's announcement the US would freeze all foreign assistance for 90 days, Byanyima said officials estimate that by 2029, there could be 8.7 million people newly infected with HIV, 6.3 million AIDS-related deaths and an additional 3.4 million children made orphans. We will see a surge in this disease, Byanyima said, speaking from Uganda. This will cost lives if the American government doesn't change its mind and maintain its leadership, she .

Pharmaceuticals & Biotech.

SECTOR | 09 Feb 2025

Medical device makers need a booster shot

Business Line

Why local manufacture of medical devices is dependent on a significant hike in import duty

Pharmaceuticals & Biotech.

SECTOR | 06 Feb 2025

Zydus Lifesciences Q3 Review One Offs Impact Margins; Systematix Recommends 'Hold', Revises Target Price

NDTV Profit

gAsacol HD which is one of the large products for Zydus in the US market, has started to decline owing to competition (Teva), the impact will be more noticeable in upcoming quarters, says Systematix

Pharmaceuticals & Biotech.

SECTOR | 03 Feb 2025

Lupin Receives USFDA Approval for Generic HIV Medication

NDTV Profit

Lupin is the exclusive first-to-file for this product, it stated.

Pharmaceuticals & Biotech.

SECTOR | 01 Feb 2025

Key CDC data on HIV and LGBTQ health resources no longer accessible online

Business Standard

Some scientists and members of the public had in recent days raced to download, save and archive various datasets, worrying that they would be removed

Pharmaceuticals & Biotech.

SECTOR | 31 Jan 2025

Wockhardt stock up 10% as Zaynich achieves 96.8% efficacy in Phase III

Business Standard

Wockhardt now intends to file a new drug application (NDA) with the USFDA and seek marketing authorisation application with European Medicines Agency (EMA)